Dianthus Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0.76Mn |
Net Profits | $-50.22Mn |
Net Profit Margins | -6598.55% |
Dianthus Therapeutics, Inc. Common Stock’s revenue jumped 294.3% since last year same period to $0.76Mn in the Q2 2026. On a quarterly growth basis, Dianthus Therapeutics, Inc. Common Stock has generated 64.36% jump in its revenue since last 3-months.
Dianthus Therapeutics, Inc. Common Stock’s net profit fell -58.76% since last year same period to $-50.22Mn in the Q2 2026. On a quarterly growth basis, Dianthus Therapeutics, Inc. Common Stock has generated -22.97% fall in its net profits since last 3-months.
Dianthus Therapeutics, Inc. Common Stock’s net profit margin jumped 59.74% since last year same period to -6598.55% in the Q2 2026. On a quarterly growth basis, Dianthus Therapeutics, Inc. Common Stock has generated 25.18% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.01 |
EPS Estimate Current Year | -1.01 |
Dianthus Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.01 - a -8.6% fall from last quarter’s estimates.
Dianthus Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.01.
Key Ratios
Earning Per Share (EPS) | -0.9 |
Dianthus Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -2.27% since last year same period to -0.9 in the Q2 2026. This indicates that the Dianthus Therapeutics, Inc. Common Stock has generated -2.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-04 | -0.93 | -0.9 | 3.23% |
2026-05-05 | -1.1 | -0.85 | 22.73% |
